Clinical trial · Observational
Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance
Early Detection of Chemotherapy-related Cardiomyopathy in Patients With Breast Cancer Using Cardiac Magnetic Resonance
NCT04510532CI-TRIAL-00066863unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer is the most common cancers among women worldwide.Although chemotherapy and surgery have greatly improved the survival rate, most types of chemotherapy have been reported to have varying degrees of cardiotoxicity. The investigators will focus on the cardiotoxicity of pyrotinib and apatinib which belong to the new tyrosine kinase inhibitors in respective chemotherapy among more subjects.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Chemotherapy Induced Systolic Dysfunction | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CMR examination | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Patients with Breast Cancer who use pyrotinib
- description
- The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given pyrotinib as having HER2-positive breast cancer with no metastasis.
- interventionNames
- Diagnostic Test: CMR examination
- label
- Patients with Breast Cancer who use apatinib
- description
- The diagnosis of Breast Cancer was made based on the clinical classification criteria. The subjects were given apatinib as having HER2-negative breast cancer with no metastasis.
- interventionNames
- Diagnostic Test: CMR examination
- label
- Control group
- description
- The controls were healthy volunteers who have normal electrocardiographic and echocardiographic results and normal CMR findings
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age between 18-70 years old. * Invasive breast cancer confirmed by Pathology * Left ventricular ejection fraction ≥ 50% * Having not received any prior systemic anti-cancer therapy for advanced disease * an Eastern Cooperative Oncology Group（ECOG） performance status 0-1 * Providing written informed consent Inclusion Criteria for Control group: * Absence of known systemic diseases * Normal examinations * Age between 18-70 years old. * Providing written informed consent Exclusion Criteria: * Age \<18 years old or \>70 years old * Documented coronary artery disease or prior angiography for coronary artery disease (\>50% stenosis). * Patients with bilateral invasive breast cancers. * Patients with metastasis of breast cancer confirmed by imaging or pathology * Patients with standard metallic contraindications to CMR or an estimated glomerular filtration rate \< 30 ml/min/1.73 m2.
References
Publications (1)
- DERIVEDChai Y, Jiang M, Wang Y, Liu Q, Lu Q, Tao Z, Wu Q, Yin W, Lu J, Pu J. Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer-The EARLY-MYO-BC study. Front Cardiovasc Med. 2023 Feb 10;10:1021937. doi: 10.3389/fcvm.2023.1021937. eCollection 2023. PMID 36844736